Nitin Jain

23.9k total citations · 1 hit paper
464 papers, 9.7k citations indexed

About

Nitin Jain is a scholar working on Genetics, Hematology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Nitin Jain has authored 464 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 258 papers in Genetics, 218 papers in Hematology and 174 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Nitin Jain's work include Chronic Lymphocytic Leukemia Research (232 papers), Acute Lymphoblastic Leukemia research (173 papers) and Chronic Myeloid Leukemia Treatments (144 papers). Nitin Jain is often cited by papers focused on Chronic Lymphocytic Leukemia Research (232 papers), Acute Lymphoblastic Leukemia research (173 papers) and Chronic Myeloid Leukemia Treatments (144 papers). Nitin Jain collaborates with scholars based in United States, Israel and India. Nitin Jain's co-authors include Hagop M. Kantarjian, William G. Wierda, Elias Jabbour, Farhad Ravandi, Naval Daver, Guillermo Garcia‐Manero, Jörge E. Cortes, Marina Konopleva, Zeev Estrov and Alessandra Ferrajoli and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nitin Jain

423 papers receiving 9.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

2017 1.6k citations Partow Kebriaei, William G. Wierda et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nitin Jain United States	49	3.8k	3.5k	3.2k	2.4k	2.3k	464	9.7k
Carlos E. Bueso‐Ramos United States	59	3.0k 0.8×	6.0k 1.7×	4.3k 1.3×	5.8k 2.4×	1.8k 0.8×	386	14.7k
Marilyn L. Slovak United States	46	4.0k 1.0×	6.9k 2.0×	2.3k 0.7×	4.4k 1.9×	2.8k 1.2×	152	11.7k
Tomoki Naoe Japan	56	2.9k 0.8×	7.9k 2.3×	2.7k 0.9×	8.1k 3.4×	2.5k 1.1×	352	15.9k
David F. Claxton United States	40	2.6k 0.7×	5.6k 1.6×	1.5k 0.5×	2.8k 1.2×	1.4k 0.6×	195	9.1k
Jonathan E. Kolitz United States	61	2.3k 0.6×	6.6k 1.9×	6.7k 2.1×	5.2k 2.2×	2.2k 1.0×	256	14.4k
Gert J. Ossenkoppele Netherlands	53	2.8k 0.7×	8.6k 2.5×	2.8k 0.9×	4.4k 1.8×	2.3k 1.0×	279	12.3k
Jane L. Liesveld United States	47	2.3k 0.6×	3.7k 1.1×	1.4k 0.4×	2.8k 1.2×	759 0.3×	252	8.3k
Daniel J. DeAngelo United States	60	4.3k 1.1×	9.0k 2.6×	3.9k 1.2×	6.2k 2.6×	4.3k 1.9×	444	16.3k
Susan M. Blaney United States	63	3.3k 0.9×	1.2k 0.3×	2.5k 0.8×	5.0k 2.1×	1.3k 0.6×	267	11.4k
Oliver G. Ottmann Germany	62	4.0k 1.0×	10.4k 3.0×	5.0k 1.6×	4.9k 2.1×	3.3k 1.4×	372	16.1k

Countries citing papers authored by Nitin Jain

Since Specialization

Citations

This map shows the geographic impact of Nitin Jain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nitin Jain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nitin Jain more than expected).

Fields of papers citing papers by Nitin Jain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nitin Jain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nitin Jain. The network helps show where Nitin Jain may publish in the future.

Co-authorship network of co-authors of Nitin Jain

This figure shows the co-authorship network connecting the top 25 collaborators of Nitin Jain. A scholar is included among the top collaborators of Nitin Jain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nitin Jain. Nitin Jain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Short, Nicholas J., Elias Jabbour, Walid Macaron, et al.. (2025). Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL. Blood Cancer Journal. 15(1). 169–169.

Ledesma, Celina, Nitin Jain, Priti Tewari, et al.. (2024). Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 2810–2810. 1 indexed citations

Bataller, Álex, Alexandre Bazinet, Gautam Borthakur, et al.. (2024). Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood. 144(Supplement 1). 4272–4272.

Bataller, Álex, Hagop M. Kantarjian, Alexandre Bazinet, et al.. (2024). Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. Blood. 144(Supplement 1). 56–56. 3 indexed citations

Shi, Chunhua, Guojun Yang, Qing Shi, et al.. (2023). Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Leukemia. 37(10). 2006–2016. 6 indexed citations

Sasaki, Koji, Fadi Haddad, Nicholas J. Short, et al.. (2023). Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019. Cancer. 129(23). 3805–3814. 17 indexed citations

Gordon, Max J., Jade Jones, Binsah George, et al.. (2023). Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer. 129(14). 2192–2200. 10 indexed citations

Jain, Nitin, James D’Olimpio, Seung‐Tae Lee, et al.. (2023). Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma. Blood. 142(Supplement 1). 3288–3288. 1 indexed citations

Thompson, Philip A., Michael J. Keating, Alessandra Ferrajoli, et al.. (2023). Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD. Leukemia. 37(7). 1444–1453. 2 indexed citations

10.

Jabbour, Elias, Koji Sasaki, Fadi Haddad, et al.. (2023). The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors. American Journal of Hematology. 98(4). 658–665. 15 indexed citations

11.

Chin, Hou-Man, et al.. (2022). Digital synchronization for continuous-variable quantum key distribution. Quantum Science and Technology. 7(4). 45006–45006.

12.

Guo, Xiaojie, et al.. (2022). 40 km fiber transmission of squeezed light measured with a real local oscillator. Quantum Science and Technology. 7(4). 45003–45003. 14 indexed citations

13.

Sasaki, Koji, Elias Jabbour, Nicholas J. Short, et al.. (2021). Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017. American Journal of Hematology. 96(6). 650–658. 79 indexed citations

14.

Richard‐Carpentier, Guillaume, Hagop M. Kantarjian, Guilin Tang, et al.. (2021). Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Advances. 5(23). 5415–5419. 25 indexed citations

15.

Jain, Nitin, Gail J. Roboz, Marina Konopleva, et al.. (2020). Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood. 136(Supplement 1). 7–8. 19 indexed citations

16.

Jabbour, Elias, Koji Sasaki, Farhad Ravandi, et al.. (2019). Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 125(15). 2579–2586. 66 indexed citations

17.

Flinn, Ian W., Susan O’Brien, Brad S. Kahl, et al.. (2017). Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood. 131(8). 877–887. 183 indexed citations

18.

Rozovski, Uri, David Harris, Ping Li, et al.. (2017). Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex. Molecular Cancer Research. 15(5). 610–618. 23 indexed citations

19.

Khan, Maliha, Hagop M. Kantarjian, Jing Ning, et al.. (2017). Response and Outcomes of Third-Line Tyrosine Kinase Inhibitor Therapy on Patients with Chronic Phase Chronic Myeloid Leukemia. Blood. 130. 2882–2882. 1 indexed citations

20.

Rozovski, Uri, Srđana Grgurević, Carlos Bueso-Ramos, et al.. (2015). Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Molecular Cancer Research. 13(5). 944–953. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact